^
Association details:
| Biomarker: | AXL expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
663 - Longitudinal AXL assessment of circulating tumor cells (CTCs) and its clinical implication in the patients with EGFR mutated non-small cell lung cancer (NSCLC)
Published date:
03/10/2021
Excerpt:
...to monitor AXL expression before and after Gefitinib treatment in EGFR mutated NSCLC patients through circulating tumor cells (CTCs)...Moreover, the PFS (p= 0.002) and OS (p= 0.007) were both worse in patients with AXL expression at the baseline status compared with patients without AXL expression (N=55)
